Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Which antidiabetic for elderly diabetes patients? It depends on their CV risk

Publish date:: June 13, 2019

Key clinical point: Deciding between newer second-line diabetes drug classes has a lot to do with whether the main concern is heart failure or cardiovascular events.

Major finding: Initiating an SGLT2 inhibitor versus a GLP-1 receptor agonist in the elderly was associated with a 34% decrease in the risk of heart failure hospitalizations, but there was a 25% increased risk of the composite primary outcome of myocardial infarction, stroke, and all-cause mortality among those without preexisting cardiovascular disease.

Study details: Review of Medicare claims data for almost 90,000 type 2 diabetes patients.

Disclosures: The work was funded by the National Institutes of Health. The lead investigator disclosed research funding from Boehringer Ingelheim and GlaxoSmithKline.

Citation:

REPORTING FROM ADA 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,